Re: Carna-aware/side-effects

[Guest guest]

I can definitely testify to the negative side effects of carnosine,

as I have already done here in the past. No one else on this list

seemed to know what I was talking about but carnosine did a

terrifying thing to my son. It made him lose balance. This is a child

who has great coordination ordinarily but when on carnosine he would

stumble and fall ALL THE TIME, getting bruises and bumps on his

forehead. As soon as I had made the connection, I discontinued it

even though it seemed to have made my boy more interactive. That was

in the fall. Incidentally, carnosine did nothing for my other,

apraxic, son. Lately I decided to give it another try and started my

younger son on a very low dose of carnosine, about 100mg a day, and

what do you know, this time HE noticed, too. He told me, several

unpleasant incidents later, " mom, I keep falling. " I stopped it for

good. The side effects eventually went away. I wonder how I could get

in touch with Dr. Chez. If anyone can send me his e-mail address,

please do so.

Thank you,

Natasha

[Guest guest]

Thanks for writing.

denise

--- In , " nataleo " <nataleo@e...>

wrote:

> I can definitely testify to the negative side effects of carnosine,

> as I have already done here in the past. No one else on this list

> seemed to know what I was talking about but carnosine did a

> terrifying thing to my son. It made him lose balance. This is a

child

> who has great coordination ordinarily but when on carnosine he

would

> stumble and fall ALL THE TIME, getting bruises and bumps on his

> forehead. As soon as I had made the connection, I discontinued it

> even though it seemed to have made my boy more interactive. That

was

> in the fall. Incidentally, carnosine did nothing for my other,

> apraxic, son. Lately I decided to give it another try and started

my

> younger son on a very low dose of carnosine, about 100mg a day, and

> what do you know, this time HE noticed, too. He told me, several

> unpleasant incidents later, " mom, I keep falling. " I stopped it for

> good. The side effects eventually went away. I wonder how I could

get

> in touch with Dr. Chez. If anyone can send me his e-mail address,

> please do so.

>

> Thank you,

>

> Natasha

[Guest guest]

You can e-mail your concerns to the carn-aware website and they forward it to

Dr. Chez and then they'll send you a response.

----- Original Message -----

Thanks for writing.

denise

> I can definitely testify to the negative side effects of carnosine,

> as I have already done here in the past. No one else on this list

> seemed to know what I was talking about but carnosine did a

> terrifying thing to my son. It made him lose balance. This is a

child

> who has great coordination ordinarily but when on carnosine he

would

> stumble and fall ALL THE TIME, getting bruises and bumps on his

> forehead. As soon as I had made the connection, I discontinued it

> even though it seemed to have made my boy more interactive. That

was

> in the fall. Incidentally, carnosine did nothing for my other,

> apraxic, son. Lately I decided to give it another try and started

my

> younger son on a very low dose of carnosine, about 100mg a day, and

> what do you know, this time HE noticed, too. He told me, several

> unpleasant incidents later, " mom, I keep falling. " I stopped it for

> good. The side effects eventually went away. I wonder how I could

get

> in touch with Dr. Chez. If anyone can send me his e-mail address,

> please do so.

>

> Thank you,

>

> Natasha

[Guest guest]

Hi Natasha,

I do recall your message, it was awhile back -and it does sound like

for whatever reason the carnosine is not at all something for your child.

I don't know you but if my child had such a reaction I would have

been on the phone with Dr. Chez back then -but it's good you are

looking into contacting him now. You are looking for Dr. Chez's

contact info

Phy - Pediatric Neurologist

G. Chez, M.D.

40 E. Scranton

P.O. Box 261

Lake Bluff, Illinois 60044

Phone (847) 735-0300

Fax (847) 735-0400

mchezmd@...

In fact -many of Dr. Chez's patients that are members here have posted Dr.

Chez's contact

information a few times already. Dr. Chez is someone who is

supported by (Cure Autism Now) CAN and that is how I heard of him. I

do know that there is some problem (political) between Dr. Chez and

some of the (Defeat Autism Now) DAN docs for some reason -I don't

know the whole story -just know there is a problem. So in other

words -someone " could " have a vested interest in posting something

that is detrimental to Dr Chez and his research. It's easy enough

to say whatever you want in an email when nobody knows who you are.

Some of us -like me -know many people in this group personally -some

don't. I'm not saying that's the case -just something I want to

throw out there based on something that is not hitting me right.

Dr. Chez -is not at all hard to find -he's a respected and much

loved pediatric neurologist -again some of his patients are part of this

group and again have posted his contact information before. Just to

check however -his bio and contact information below took me all of

a second at google to find.

In general -if you see something like sudden lose of coordination -

that is serious. It is interesting that not only did you not report

seeing a neurologist with this new found incoordination -but that

you have yet to contact Dr. Chez or share Dr Chez's information with

your child's neurologist -or you would have his contact info.

Sudden incoordination could be a sign of a dangerous side effect of

a drug -or...it could be a sign of a number of severe neurological

conditions.

" Promptly report warning signs or symptoms to your doctor. The

warning signs for stroke are a sudden, unexplained tingling and/or

numbness on one side of the body, a sudden severe headache, blurred

vision, difficulty talking, stumbling and/or sudden clumsiness.

Sometimes a mini-stroke, lasting only a few moments and called a

transient ischemic attack (TIA), comes before a stroke. "

http://www.familymanagement.com/aging/stroke.prevention.html

In addition -you even tried using carnosine again? Why? If you

have not -please get to a neurologist and share all of this. Do you

belong to a local support group? What state are you in?

Also does your child have any strange reactions to meat or poultry?

(carnosine is an amino acid found naturally in meat and poultry)

http://www.smart-publications.com/articles/021113-carnosine.html

We have for the most part a highly intelligent free thinking group

without censorship of views or sharing of information outside of

slander -therefore -yours from the last time you posted it till now

is still the only message of it's kind here -and of it's kind on the

internet -and I searched all over.

I'll go out on a limb here and say that based on your sole email -

and after all the searching I've done -as a parent I continue to

give carnosine to my son Tanner -and myself now here and there (hey

it's being studied for it's anti aging properties and all that meet

me think I'm way younger -I even got proofed recently again!!) I do

not feel any changes on the carnosine as I do the EFAs. Based on my

own experience -and on the respect of Dr. Chez (he has much to lose

in going out on the carnosine limb -way more than those that post

here anonymously) I still believe that carnosine is a good

product that works for many -not as many as the EFAs -but it's

something worth exploring more with your child's MD. Unlike EFAs in

our population -there is Dr. Chez's clinical research -and the

testimony of his patients here -that make me believe in carnosine.

Unlike others -I don't read a message like yours and say " a ha -I

knew there was something wrong with it -nothing's that good " If

your message is not accurate I think of the reason I state above -

and if it is accurate -I think... " there is something in the

carnosine that must be passing the blood brain barrier -and this is

proof of that! " And then yours must be a rare side effect to watch

out for -we would have to know the child's family history and

medical background however to be able to even say that.

Again as far as I know -yours is the only child who had such an

experience on carnosine -and as we know with EFAs -what we view as

negative may or may not be (like to the mother who posted about more

hyper activity on EFAs -if you check the archives -many others

responded that was the sign of the breakthrough right before the

surge -and then the hyper activity either stayed -or in most cases

went away. Some parents in this group have to decide between a more

hyper child -who is also more talkative -or a less active less

talkative child -and the answer is the obvious -hyper and talkative)

Many of you ask questions as if there is one answer -there isn't

enough research to have them all. So keep sharing -and don't

overreact to any one email.

Here is an article about Dr. Chez -and then his bio (again in case it's missed

above) and contact

info. Any MD out there researching and going out on the limb for

our children is a hero in my book. So to sum up - get to

a neurologst and share all the information -and in your case don't

give your child anything until you do this.

" and Jane have been taking a synthetic version of a natural

protein called l-carnosine. Their pediatric neurologist, Dr.

Chez, of Lake Bluff, has recently completed the first study of the

substance.

" It affected language, receptive language, eye contact,

communication, all of which are things which children with autism

have big gaps with, " Chez said.

Over an eight-week period, Chez's study showed that carnosine

improved behavior and communication by 16 percent. Social

interaction improved by 27 percent and, in just four weeks, parents

reported an overall improvement that more than doubled through the

length of the study.

Lites said that more and more research shows that the frontal lobes

and the temporal lobes in the brain control emotion, epileptic

activity, cognitive, expressive speech, and abstract thinking.

Chez said I-carnozine apparently works in the front part of the

brain. So far, he said he's used it on about 1,000 children, with a

90 percent success rate. "

http://www.wnbc.com/drdavidmarks/1715238/detail.html

G. Chez, M.D

Dr. G. Chez received his Bachelor of Science in 1981 at

Indiana University with honors. He received his M.D. Degree from the

Indiana University School of Medicine in 1985. He served his

internship and residency in Pediatrics at s Hopkins Hospital

from 1985-1987. He was awarded a fellowship in child neurology at

Children's Memorial Hospital in Chicago and another fellowship at

the Cleveland Clinic Foundation in Cleveland. He was also awarded a

fellowship in Epilepsy at Rush Presbyterian-St. Luke's Medical

Center.

Dr. Chez is certified by the National Board of Medical Examiners I-

III, the American Board of Pediatrics, and the American Board of

Psychiatry and Neurology, with special competence in Child

Neurology.

Dr. Chez was recently awarded two Unrestricted Educational Grants by

Elan Pharmaceuticals and Pfizer, Inc. for research in Tourette's

Syndrome and Epilepsy. He was also awarded a grant by the Citizen's

United for Research on Epilepsy (CURE) for research on Epilepsy. He

has published numerous articles on topics in Neurology.

Dr. Chez treats the following Neurologic disorders: Bell's Palsy,

Cephalic Disorders, Cerebral Palsy, Guillain-Barre Syndrome,

Headache, Infectious Diseases, Migraine, Movement Disorders, Seizure

Disorders (Epilepsy), Sleep Disorders, Tremor, Tumors, Vertigo,

Autism, ADHD, Tic Disorders, and Tourette's Syndrome. He has

expertise in the following diagnostics: Lumbar punctures and EEG.

CURRICULUM VITAE

G. Chez, M.D.

40 E. Scranton

P.O. Box 261

Lake Bluff, Illinois 60044

Phone (847) 735-0300

Fax (847) 735-0400

mchezmd@...

CURRENT POSITIONS

Founder, G. Chez, M.D. Pediatric Neurology, S.C.

Main Office: Lake Bluff, Illinois November 2000 – Present

Founder, G. Chez, M.D. Pediatric Neurology, S.C.

Lake Forest, Illinois January 1995 – November 2000

Assistant Professor in Neurology and Epilepsy, Rush Medical School

Attending, Pediatrics, Rush Presbyterian-St. Luke's Medical Center

Chicago, Illinois 1990 - Present

Lecturer, Child Neurology, Chicago Medical School September 1998 -

Present

Medical Director, Pediatric Epilepsy and Lake Forest Ketogenic Diet

Program

Lake Forest Hospital

Lake Forest, Illinois 60045

1995 - Present

Attending Staff, Department of Pediatrics, Lutheran General Hospital

Park Ridge, Illinois

STAFF PRIVILEGES

Lake Forest Hospital, Lake Forest, Illinois

Highland Park Hospital, Highland Park, Illinois

Lutheran General Hospital, Park Ridge, Illinois

Rush Presbyterian-St. Luke's Medical Center, Chicago, Illinois

Hoffman Estates Medical Center, Hoffman Estates, Illinois

PRIOR APPOINTMENTS

Associate Director, Pediatric Neurology

Co-Director Pediatric Epilepsy Program

Lutheran General Hospital

EDUCATION AND TRAINING

Epilepsy Fellowship

Rush Presbyterian-St. Luke's Medical CenterJanuary 1991 - June 1992

Child Neurology Fellowship

Year 1:Children's Memorial Hospital

Northwestern University

Chicago, Illinois1987-1988

Year 2 & 3:Cleveland Clinic Foundation

Cleveland, Ohio1988-1990

Pediatric Residency

s Hopkins Hospital

Pediatrics

Baltimore, land1986-1987

Internship

s Hopkins Hospital

Pediatrics

Baltimore, land1985-1986

Medical

Indiana University School of Medicine

M.D. Degree1985

Undergraduate

Indiana University

B.S. Microbiology

Honors1981

HOSPITAL APPOINTMENTS

Lake Forest Hospital

Lake Forest, Illinois60045

Full Staff PrivilegesSeptember 1993 - Present

Lutheran General Hospital

Park Ridge, Illinois 60068

Full Attending Staff PrivilegesDecember 1992 - Present

Rush Presbyterian-St. Luke's Medical Center

Chicago, Illinois 60612

Attending Staff, Pediatric Neurology & PediatricsAugust 1990 -

Present

Cleveland Clinic Foundation

Lake Forest, Illinois60045

Cleveland, Ohio

Clinical Associate in Pediatrics1989-1990

Prentice Hospital

Northwestern University

Chicago, Illinois

Clinical Associate in Pediatrics1987-1988

AWARDS AND GRANTS

Novartis Pharmaceuticals, Open-label Trial of Exelon in

Autistic Children-$60,0002001

Elan Pharmaceuticals, Unrestricted Educational Grant-$24,000

Study of Zanaflex for Tic Dysfunction in Tourette's Syndrome2000

Citizens United for Research in Epilepsy (CURE)-$7,700

Grant for Autoantibody Research in Epilepsy2000

Pfizer Inc., Unrestricted Educational Grant

Preliminary Study of Aricept in Autistic Children2000

Dr. G. Chez Fund for Epilepsy and Autism ResearchEstablished

1999

CAN Award for Immunology-$20,000

Autism Research in conjunction with

Washington University of St. Louis1997

Rush Women's Board-$20,000

Ketogenic Diet Study Grant1997

SIGMA TAU Pharmaceutical-$24,000

Carnitine in Ketogenic Diet1997

Digitrace Epilepsy Research Grant-$3,0001995

Co-Investigator; Cleveland Clinic Foundation

Grant (Primary Investigator: Blaise Bourgois, M.D.,

Department of Epilepsy)1989-1990

Research Honors Award

Indiana University School of Medicine1985

Arthur Richter Award in Child Psychiatry

Indiana University School of Medicine1984

Educational Grant

Porter County Physicians Association

Valparaiso, Indiana1981-1985

BOARD CERTIFICATION AND ELIGIBILITY

National Board of Medical Examiner I-III1986

American Board of PediatricsNovember 1991

Re-Certified, 1998

American Board of Psychiatry and Neurology with

Special Competence in Child Neurology

Part I (passed)April 1991

Part II (passed)October 1991

LICENSES

Illinois license since July 1987, Full Medical Privileges

DEA license since July 1987

COMMUNITY INVOLVEMENT

Professional Advisory Board

Cure (Citizens United Research in Epilepsy)1998-Present

CAN Clinical Advisory Board1997-Present

Medical Advisory Board

CAN (Cure Autism Now)1996-1997

Professional Advisory Board

Epilepsy Foundation of Metropolitan Chicago1997-Present

Professional Advisory Board

Pathways Center for Children

Glenview, Illinois1995-1996

Member, Board of Directors

SEDOL Foundation1995-Present

Professional Advisory Board

Epilepsy Services of Northern Illinois

Highland Park, Illinois1992-Present

PROFESSIONAL ASSOCIATIONS

Child Neurology Society

American Academy of Pediatrics

American Academy of Neurology

American Epilepsy Society

American Society of Clinical Neurophysiology

PUBLICATIONS

Book chapters:1.Chez, M.G. Headache, facial pain, and chronic pain.

In: Bone, R., & Rosen, R., eds. Quick Reference to Internal

Medicine. New York: Igaku-Shoin, 1994: 1445-1452.

2.Chez, M.G., Buchanan C., Loeffel, M., Field-Chez, M., Nowinski,

C., Bardenstein R., & Hammer, M. Practical treatment with pulse-dose

corticosteroids in pervasive developmental delay or autistic

patients with abnormal epileptiform sleep EEG and language delay.

In: Perat, M.V., ed. New Developments in Child Neurology,

Proceedings of the 8th World Congress of Child Neurology. Monduzzi

Editore: Bologna, Italy, 1998: 695-698.

3.Chez, M.G., Buchanan C., Bagan, B., Hammer, M., McCarthy, K.,

Ovrutskaya, I., Nowinski, C., & Cohen, Z. A two part clinical study

of secretin in the treatment of autism. In: Evrard, P., Richelme,

C., & Tardieu, M., eds. Third European Paediatric Neurology Society

Congress. Monduzzi Editore: Bologna, Italy, 1999: 55-59.

Papers:1.Chez, M.G., , R. G. Altered metabolic incorporation

of fucose and leucine into PNS myelin of 25-week-old diabetic

(C57BL/Ks[db/db]) mice: Effects of untreated diabetes on nerve

metabolism. Neurochemical Research 1983; 9 (40): 465-472.

2.Szombathy, S.P. Chez, M.G., Laxer, R.M. Acute septic arthritis

due to acremonium. J. Rheum 1988; 15 (4): 714-715.

3.Chez, M.G., Sila C.A., Ransohoff, R.M., and Longworth, D.L.

Ibuprofen induced meningitis: Detection of intrathecal IgG synthesis

and immune complexes. Neurology 1989; 39 (12): 1578-1580.

4.Pranzatelli, M.R., Kao, P.C., Tate, E.D., Chaves, E., Chez, M.G.,

Dobyns, W.B., Kang, H., Rothner, D.A.: Antibodies to ACTH in

opsoclonus-myoclonus. Neuropediatrics 1983; 24.

5.CChez, M.G., Bourgois, B.F.D., Pippenger, C.E., Knowles, W.D.

Pharmacodynamic interactions between phenytoin and valproate:

Individual and combined anti-epileptic and neurotoxic actions in

mice. Clinical Neuropharmacology 1994; 17 (1): 32-37.

6.Morrell, F., Whisler, W.W., , M.D., Hoepner, T.J., DeTeledo

Morrell, L., Pierre-Louis, J.C., Karmer, A., Bielow, J., Bergen, D.,

Chez, M., Hasegawa, H. Landau-Kleffner Syndrome: Treatment with

subpial intracortical transection. Brain 1995; 118: 1529-46.

7.Chez, M.G. Buchanan, C., Field-Chez, M., Loeffel III, M.F., &

Hammer, M.S. Treatment of electroencephalographic epileptiform

activity on overnight EEG studies in children with pervasive

developmental delay or autism: defining similarities to the Landau-

Kleffner syndrome. Journal of Development and Learning Disorders

1998; 2(2): 217-229.

8.Chez, M.G., Hammer, M.S., Loeffel, M., Nowinski, C. Clinical

experience of three pediatric and one adult case of spike and wave

status epilepticus treated with injectable depacon (valproic acid).

Journal of Child Neurology 1999; 14(4): 239-242.

9.Lewin, J.D., s, A., Chez, M.G., Patil, A., Devinski, O.,

, M., Kanner, A., , J.T., Funke, M., , G., Chong, B.,

Provencal, S., Weisend, M., Lee, R.R., Orrison, Jr., W.W.

Magnetoencephalographic patterns of epileptiform activity in

children with regressive autism spectrum disorders. Pediatrics 1999;

104(3): 405-418.

10.Connolly, A.M., Chez, M.G., Pestronk, A., Arnold, S.T., Mehta,

S., Deuel, R.K. Serum autoantibodies to brain in Landau-Kleffner

variant, autism, and other neurologic disorders. Journal of

Pediatrics 1999; 134(5): 607-613.

11.Sandler, R.H., Bolte, E.R., Chez, M.G., Schrift, M.J. Relief of

psychiatric symptoms in a patient with Crohn's disease after

metronidzole therapy. Clinical Infectious Diseases 1999; in press.

12.Chez, M.G., Buchanan, C.P., Bagan, B.T., Hammer, M.S., McCarthy,

K.S., Ovrutskaya, I., Nowinski, C.V., Cohen, Z.S. Secretin and

autism: a two part clinical investigation. Journal of Autism and

Developmental Disorders 2000; 30(2): 87-94.

13.Chez, M.G., Buchanan, C.P. Reply to B. Rimland's " comments

on `secretin and autism: a two-part clinical investigation. " Journal

of Autism and Developmental Disorders 2000; 30(2): 97-98.

14.Chez, M.G., Hammer, M.S., Loeffel, M.F., Nowinski, C.V., &

Bagan, B.T. Clinical experience of three pediatric and one adult

case of spike-and-wave status epilepticus treated with injectable

valproic acid [Review]. Neurology Review Journal 2000; in press.

15.Chez, M.G., Field-Chez, M., Nowinski, C., Buchanan, C.,

Ovrutskaya, I. Relationship of epileptic activity in autism and

pervasive developmental disorder to possible autoimmune

encephalopathy. Journal of Developmental and Learning Disorders

2000; in press.

Abstracts:1., D.R., Chez, M.G., Lawson, J.A., Seeger, C.A.,

, R.G. Peripheral neuropathy in osmotic mini-pump insulin

treated rats. Clinical Research 1983; 31 (4): 810AS.

2.Lawson, J.A., Chez, M.G., , D.R., Seeger, C.A., ,

R.G. The direct effect of insulin on myelin metabolism. Clin.

Research 1983; 3 (4): 814A.

3.Chez, M.G., , R.G. Altered metabolic incorporation of

fucose and leucine into PNS myelin of 25-week-old diabetic (C57BL/Ks

[db/db] mice. Clin. Research 1983: 31 (4); 810AS.

4.Chez, M.G., Sila, C.A. Intrathecal synthesis of immune complexes

and immunoglobulins in Ibuprofen-induced chemical meningitis.

Neurology 1989; Suppl 1: 384.

5.Chez, M.G. Rothner, A.D., Chou, S.M. Vascular complications of

neurofibromatosis. ls of Neurology 1989; 26 (3): 484.

6.Chez, M.G., Rothner, A.D., Baetz-Greenwalt, G., Weinstein, M.

Adenovirus-induced cervical myelopathy: MRI and clinical

correlation. ls of Neurology, September, 1990.

7.Chez, M.G., Rothner, A.D., Sila, C.A., and Moodle, D.S.

Cardiolipin antibodies, stroke and mitral valve vegetation in a

pediatric patient. ls of Neurology, September, 1990.

8.Chez, M.G., Enenberg, G.E., and Rosenkranz, E. Post-cardiac

surgery choreoathetosis: MRI and clinical findings. ls of

Neurology, September, 1990.

9.Chez, M.G., Rothner, A.C., Cruse, R.P., Gebara, S., Wyllie, R.,

and Baetz-Greenwalt, B. Progressive peripheral neuropathy of

childhood onset with chronic idiopathic pseudo-obstruction. ls

of Neurology, September, 1990.

10.Chez, M.G., and Cruse, R.P. Treatment of refractive dystonia

with carbamazepine and high dose baclofen combination therapy.

ls of Neurology, September, 1990.

11.Chez, M.G., Bourgois, B.F.D. Pharmacodynamic interactions

between phenytoin and valproate: Individual and combined epileptic

and neurotoxic actions in mice. Epilepsia 1990; 31 (Suppl 3).

12.Chez, M.G., Soglin, D. Ketorolac tromethamine (Toradol)

treatment in children with acute migraine. ls of Neurology 1991;

30 (3): 494.

13.Pranzatelli, M.R., Kaa, P.C., Tate, E.D., Chaves, E., Chez,

M.G., Dobyns, W.B., Kang, H. Adrenocorticotrophic hormone in

opsoclonus-myoclonus. ls of Neurology 1991; 30 (3): 471.

14.Chamlin, S.L., Chez, M.G., Heydeman, P.T., VanSlyke, P.

Prednisone therapy in Landau-Kleffner Syndrome: Improved speech

performance and correlating EEG changes. ls of Neurology 1992;

32 (3): 476.

15.Chez, M.G., Major, S.M., , M.G., Pierre-Louis, S., Ali, A.,

Morrell, F. SPECT evaluation of cerebral perfusion series in Landau-

Kleffner Syndrome: Correlation to EEG epileptiform abnormalities.

Epilepsia, Nov./Dec., 1992.

16.Morrell, F., Whisler, W.W., Hoeppner, T.J., , M.D., Kanner,

A.M., Pierre-Louis, S.J., Chez, M.G., Hasagawa, H. Electrophysiology

of heterotropic grey matter in the " double cortex " syndrome.

Epilepsia, Nov./Dec., 1992.

17.Hoeppher, T.M., Morrell, F., , M.D., Chez, M.G., Hasegawa,

H. The Landau-Kleffner Syndrome: A perisylvian epilepsy. Epilepsia,

Nov./Dec., 1992.

18.Morrell, F., Whisler, W.W., , M.D., Pierre-Louis, S.J.,

Hoeppher, T.J., Chez, M.G.,Hasegawa, H. Clinical outcome in Landau-

Kleffner Syndrome treated by multiple subpial transection.

Epilepsia, Nov./Dec., 1992.

19., M.D., Pierre-Louis, S.J. Kanner, A.M., Morrell, F., Chez,

M.G., Hasegawa, H. Whisler, W.W., Clasen, R., Cochran, E.

Pathological spectrum of acquired epileptic aphasia of childhood.

Epilepsia, Nov./Dec., 1992.

20.Chez, M.G., Glauser, T.A., Pippenger, C.E. Superoxide dismutase

overactivity, excessive selenium, and low copper in acquired

epileptic aphasia (The Landau-Kleffner Syndrome). ls of

Neurology 1995; 39 (3): 544.

21.Chez, M.G., Glauser, T.A., Pippenger, C.E. Catalase and Divalent

Cation Deficiency in Infantile Spasms. Epilepsia 1995; 36 (4): 107.

22.Chez, M.G., Glauser, T.A., Pippenger, C.E. Superoxide dismutase

overactivity, excessive selenium, and low copper in acquired

epileptic aphasia (The Landau-Kleffner Syndrome). ls of

Neurology 1995; 39 (3): 544.

23.Chez, M.G., Glauser, T.A., Pippenger, C.E. Catalase and divalant

cation deficiency in infantile spasms. Epilepsia 1995; 36 (4): 107.

24.Chigani, D.C., daSilva, E., Chez, M.G. , M., Morrell, F.,

Chugani, H. [C-11] Flumazenil PET demonstrates focal abnormalities

in Landau-Kleffner syndrome. Epilepsia 1995; 36 (4): 123.

25.Chez, M.G. Clinical spectrum of patients referred for Landau-

Kleffner syndrome previously diagnosed with pervasive developmental

delay or dutism: EEG, HMPAO SPECT, and steroid response data.

Neurology 1996; 46: A115.

26.Chez, M.G., Buchanan, C.P. EEG abnormalities, otitis media, and

age of speech regression in pervasive developmental delay:

Relationship to Landau-Kleffner syndrome/epileptic aphasia.

Epilepsia 1996; 37 (Suppl. 5): 104.

27.Chez, M.G., Buchanan, C.P., Kessler, J., Demski, P., Wagner, E.

Carnitine deficiency in patients starting the ketogenic diet.

Neurology 1997; 48: A110.

28.Chez, M.G., Buchanan, C.P. Landau-Kleffner Syndrome (LKS):

Normalization of EEG with ketogenic diet after partial response to

steroids, valproate, and IVIG. Epilepsia 1997; 38 (Suppl 3): 129.

29.Chez, M.G., Buchanan, C.P. Age of regression of language and

behavior in children referred for pervasive developmental delay

correlates to severity of epileptiform activity on 24-hour EEG.

Epilepsia 1997; 38 (Suppl 3): 50.

30.Chez, M.G., Buchanan, C.P. Clinical spectrum of patients

referred for Landau-Kleffner Syndrome: EEG, SPECT, and steroid

response data. Epilepsia 1997; 38 (Suppl 3).

31.Connelly, A.M., Chez, M.G., Pestronk, A., Arnold, S., Mehta, S.,

Buchanan, C., Zucker, M., Deuel, R. Serum autoantibodies to human

temporal lobe cortex in children with epilepsy and language

dysfunction. ls of Neurology 1997; 42 (3): 490.

32.Chez, M.G., Buchanan, C.P., Zucker, M.J., May, B. Value of 24-

hour EEG vs. routine EEG in detecting occult epileptic activity in

children with pervasive developmental delay. ls of Neurology

1997; 42 (3): 509.

33.Lewin, J., Chez, M., s, R., Dembski, O., , M., ,

J., Orrison, W. Neuromagnetic evaluation of children with acquired

developmental aphasia. Epilepsia 1997; 38 (8): 128.

34.Bardenstein, R., Chez, M.G., Helfand, B., Buchanan, C., Zucker,

M. Improvement in EEG and clinical function in pervasive

developmental delay (PDD): Effect of valproic acid. Neurology 1998;

50 (Suppl 4): A86.

35.Buchanan, C.P., Chez, M.G., Bardenstein, R., HMPAO Spectroscopy

in pervasive developmental delay and autism: Correlation with 24-

hour EEG. Journal of Neuropsychiatry and Clinical Neurosciences

1997; 9(4): 701.

36.Buchanan, C., Ovrutskaya, I., Chez, M.G., Loeffel, M., Hammer,

M.S. Reasons for dropping out of the ketogenic diet: Behavioral non-

compliance vs. physical side effects. ls of Neurology 1998; 44

(3): 566.

37.Chez, M.G., Loeffel, M., Buchanan, C., Hammer, M.S., Field-Chez,

M. Preponderance of right-sided abnormalities observed in 24-hour

EEG and SPECT in children with autism spectrum disorders. Epilepsia

1998; 39.

38.Helfand, B.T., Chez, M.G., Bardenstein, R., Buchanan, C., &

Loeffel, M.F. Improvement in EEG and clinical function in pervasive

developmental delay (PDD): Pharmacological effects of monotherapy

and combination therapy using valproic acid and prednisone.

Epilepsia 1998; 39.

39.Chez, M.G., Loeffel, M., Buchanan, C., and Field-Chez, M. Pulse

high dose steroids as combination therapy with valproic acid in

epileptic aphasia patients with pervasive developmental delay or

autism. ls of Neurology 1998; 44 (3): 539.

40.Goodell, W., Chez, M.G., Buchanan, C., Hammer, M.S., Loeffel, M.

Bone marrow suppression from copper deficiency in two patients on

the ketogenic diet. ls of Neurology 1998; 44 (3): 568.

41.Hammer, M.S., Chez, M.G. Stack, C.V., Loeffel, M., Buchanan, C.

Outcome of children treated with Topirimate. ls of Neurology

1998; 44 (3): 568.

42.Chez, M.G., Bagan, B.T., Buchanan, C.P., Ovrutskaya, I., Wagner,

E. Serum b-Hydroxybutyrate levels in patients treated with the

ketogenic diet correlate with improved seizure control. Neurology

1999; 52 (Suppl. 2): A415.

43.Chez, M.G., Hammer, M.S., Bagan, B.T., Buchanan, C.P., McCarthy,

K.S., Ovrutskaya, I., Nowinski, C.V., Cohen, Z.S. Secretin used in

the treatment of autism: A double-blind clinical trial in children.

ls of Neurology 1999; 46 (3): 523.

44.Connolly, A.M., , W., Pestronk, A., Mehta, S., Choksi,

R., -Terrada, M.J.M., Puri, V., Reggin, J.D., Allan, W.C.,

Rioux, S.D., Goldstein, E., Chang, R., Chez, M., Kossak, B.,

Horwitz, C., Noetzel, M. Serum IgM autoantibodies in patients with

paraneoplastic and idiopathic opsoclonus myoclonus syndrome

recognize neurofilament and histone in neural preparations. ls

of Neurology 1999; 46 (3): 536.

45.Chez, M.G., Buchanan, C.P., Bagan, B.T., Hammer, M.S., McCarthy,

K.S., Ovrutskaya. I., Nowinski, C.V., & Cohen, Z.S. Secretin and

autism: A two-part clinical investigation. European Journal of

Paediatric Neurology 1999; 3(6): A141.

46.Buchanan, Cathleen P., Chez, G., Nowinski, Caralynn.

Zinc supplementation is effective for children with hair loss due to

chronic valproic acid therapy or the ketogenic diet. ls of

Neurology 2000; 48(3): 523.

47.Chez, G., Nowinski, Caralynn V., Buchanan, Cathleen P.

Donepezil (Aricept) use in children with autistic spectrum

disorders. ls of Neurology 2000; 48(3): 541.

48.Chez, G., Nowinski, Caralynn V., Buchanan, Cathleen P.

Presence of gastrointestinal symptoms in children with primary

diagnoses of autistic disorder. ls of Neurology 2000; 48(3): 542.

49.Nowinski, C., Chez, M., Buchanan, C. The effects of the

ketogenic diet on children with cognitive epilepsies. Epilepsia

2000; 41(7): 177.

50.Chez, M.., Connolly, A., Nowinski C., Buchanan, C. The presence

of autoantibodies in idiopathic/acquired versus genetic variants of

pediatric epilepsy. Epilepsia 2000; 41(7): 183.

51.Buchanan, C., Chez, M., Nowinski, C. Pulse-dose steroids as add-

on therapy in patients with pediatric epilepsy. Epilepsia 2000; 41

(7): 183.

PLATFORM PRESENTATIONS AND MAJOR LECTURES

1.Platform: Novartis Conference and Workshop. Boulder, Colorado.

Topic: Neurological Disoders and Treatment Options. March 2001.

2.Platform: Cyberonics: VNS and Adolescence Symposium & Workshop.

Orlando, Florida. Topic: The Ketogenic Diet. March 2001.

3.Lecture: Lake Forest Hospital. Lake Forest, Illinois. Topic: A

New Look at Autism in the New Millenium. January 2001

4.Platform: National Alliance for Autism Research. White Plains,

New York. Topic: Medications to Restore Speech in Autism. November

2000.

5.Platform: Interdisciplinary Council on Developmental and Learning

Disorders. McLean, Virginia. Topic: Medications to Restore Speech in

Autism. November 2000.

6.Platform: Autism Society and Children's Hospital Medical Center.

Cincinnati, Ohio. Topic: Modifying Symptoms of PDD/Autistic Spectrum

Disorders Through Medical Intervention. August 2000.

7.Lecture: Lake Forest Hospital. Lake Forest, Illinois. Topic: A

New Look at Autism in the New Millenium. January 2000.

8.Platform: Child Neurology Society Meeting. Nashville, Tennessee.

Topic: Secretin and autism. October, 1999.

9.Platform: European Pediatric Neurology Society. Nice, France.

Topic: Secretin and autism. November, 1999.

10.Grand Rounds. Rush Medical School. Department of Pediatrics.

Topic: Steroid use in epilepsy. June, 1999.

11.Faculty Lecturer. Interdisciplinary Council on Developmental and

Learning Disabilities Conference. Approaches to Developmental and

Learning Disorders in Infants and Children. Rockville, land.

Topic: New Biomedical Approaches for Autistic Spectrum Disorders.

November 15, 1997.

12.Grand Rounds. town University Medical School. Department

of Pediatrics. November 14, 1997.

13.Platform: World Epilepsy Congress. Dublin, Ireland. Topic: Age

of Regression of Language and Behavior in Children Referred for

Pervasive Developmental Delay: Correlation to Severity of

Epileptiform Abnormality on 24-Hour EEG. June 27, 1997.

14.CAN Conference. Autism and Epilepsy. Chicago, Illinois.

September 27, 1997.

15.CAN Autism and Epilepsy Lecture. Los Angeles, California.

December 8, 1996.

16.Grand Rounds. University of Southern California Children's

Hospital. December 7, 1996.

17.CAN Autism and Epilepsy Lecture. New York City. July 22, 1996.

18.Platform: American Academy of Neurology. San Francisco,

California. Topic: Autism and Landau-Kleffner Syndrome. March 25,

1996.

19.Platform: Speech and Language Autism Conference. Bloomingdale,

Illinois. October, 1995.

20.Platform: American Academy of Neurology. Topic: Ibuprofen-

Induced Meningitis. April, 1990.

REFERENCES

References provided upon request.

Revised April, 2001.

http://www.neurologychannel.com/pediatricneuro/physicians.shtml

=====

[Guest guest]

If you check on the autism treatment or ,

there has been a discussion of carnosine and its positive and

negative side effects. My PDD son did not do well on carnosine - for

him it increased his OCD tendencies - lining things up, shutting all

the doors, etc. We did see an increase in socialization, but the

downsides of the OCD stuff made us stop the carnosine.

Hope that helps,

Carole (who is not a big fan of DAN doctors)